[1]周广文 向楠△ 沈霖 杨艳萍 帅波 马陈.加味青娥丸对绝经后骨质疏松症患者的骨密度、骨代谢 标志物及血清MGP水平的影响[J].中国中医骨伤科杂志,2016,24(03):4-8.
 ZHOU Guangwen XIANG Nan SHEN Lin YANG Yanping SHUAI Bo MA Chen.Effects of Modified Qing'e Pills on Bone Mineral Density, Bone Metabolic Markers and Serum MGP Level in Postmenopausal Osteoporosis Women[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2016,24(03):4-8.
点击复制

加味青娥丸对绝经后骨质疏松症患者的骨密度、骨代谢 标志物及血清MGP水平的影响
分享到:

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第24卷
期数:
2016年03期
页码:
4-8
栏目:
临床研究
出版日期:
2016-03-03

文章信息/Info

Title:
Effects of Modified Qing'e Pills on Bone Mineral Density, Bone Metabolic Markers and Serum MGP Level in Postmenopausal Osteoporosis Women
文章编号:
1005-0205(2016)03-0004-05
作者:
周广文1 向楠1△ 沈霖2 杨艳萍2 帅波2 马陈2
1.湖北中医药大学(武汉,430065)
2.华中科技大学同济医学院附属协和医院
△.通信作者 E-mail:xiangnan61@sina.com
Author(s):
ZHOU Guangwen1 XIANG Nan2△ SHEN Lin2 YANG Yanping2 SHUAI Bo2 MA Chen2
1.Hubei University of Traditional Chinese Medicine,Wuhan 430065,China;
2.Union Hosp ital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China.
关键词:
加味青娥丸 绝经后骨质疏松症 基质gla蛋白 骨密度 骨代谢标志物
Keywords:
modified Qing'e Pills postmenopausal osteoporosis matrix gla protein bone mineral density bone metabolism markers
分类号:
R274.39
文献标志码:
A
摘要:
目的:观察加味青娥丸对绝经后骨质疏松症(PMOP)患者基质gla蛋白(MGP)水平、骨密度(BMD)及骨代谢指标的影响。方法:选择PMOP患者108例,随机分为A组(安慰剂对照组)、B组(加味青娥丸低剂量组)及C组(加味青娥丸高剂量组),治疗24周。另取26名BMD正常绝经妇女作为正常组。分别在治疗前与治疗24周后,采用酶联免疫吸附实验(ELISA)测定MGP水平,通过聚合酶链式反应(PCR)检测血清MGP mRNA水平,化学发光检测血清Ⅰ型胶原羧基端肽(β-CTX)、血清Ⅰ型前胶原N-端前肽(P1NP)水平,双能X线吸收法(DEXA)测定腰椎正位、 股骨颈、 Ward's三角和大粗隆的BMD。结果:治疗后C组与B组均能增加血清MGP水平及MGPmRNA的表达(P<0.05或P<0.01),而A组和正常组指标变化不明显(P>0.05)。治疗后C组与B组BMD均有不同程度的提高(P<0.05),C组对股骨颈及Ward's三角的效果更为显著,A组和正常组BMD均下降,差异无统计学意义(P>0.05)。C组能显著降低血清中的骨代谢标志物(PINP,CTX)(P<0.01),而B组仅对β-CTX有降低作用(P<0.05); A组则无明显作用(P>0.05)。结论:加味青娥丸能够提高血清MGP水平及MGP mRNA的表达,增加PMOP的BMD,降低患者骨代谢标志物,并且其效果跟用药剂量正相关。
Abstract:
Objective:To study the effects of Modified Qing'e Pills on serum MGP level,bone mineral density and bone metabolic markers in women with postmenopausal osteoporosis.Methods:108 postmenopausal osteoporosis patients were randomly divided into group(Placebo control group),B group(Modified Qing'e Pills lower dose group)and C group(Modified Qing'e Pills higher dose group).All the patients in three groups received treatment for 24 weeks.Another 26 women with normal BMD were assigned to normal group.Before and after the treatment for 24 weeks,serum MGP was measured by enzyme-linked immunosorbent assay(ELISA)while MGP mRNA was measured by Fluorescent real-time quantitative polymerase chain reaction(PCR).The serum levels of β-CTX、P1NP were measured by electrochemiluminescence(ECL).BMD was analyzed by dual energy X-ray absorptiometry(DXA).Results:After 24 weeks treatment,MGP and MGP mRNA were improved obviously in C group and B group(P<0.05 or P<0.01),while no obvious changes of MGP and MGP mRNA in normal group and A group(P>0.05).The BMD of C group and B group were all improved significantly(P<0.05),and the BMD of C group in femoral neck and Ward's triangle increased more significantly(P<0.01).The BMD of normal group and A group were decreased.All the bone metabolism markers of C group reduced obviously(P<0.05),whereas only the bone absorption marker β-CTX decreased in B group(P<0.05).The normal group and A group had no obvious clinical effects(P>0.05)Conclusion:Modified Qing'e Pills can benefit postmenopausal osteoporosis patients through improving the serum MGP levels and MGP mRNA expression,increasing bone mineral density and inhibiting bone metabolism.

参考文献/References:

[1] Xu XJ,Shen L,Yang YP,et al.Serum sclerostin levels associated with lumbar spine bone mineral density andbone turnover markers in patients with postmenopausal osteoporosis[J]. Chinese Med(Engl),2013,126(13):2480-2484.
[2] 崔莹,冯正平.抗骨质疏松药物的研究进展[J].中国骨质疏松杂志,2015,21(3):367-371.
[3] 吴海洋,索欢,王平,等.绝经后骨质疏松症的临床中药治疗进展[J].中国骨质疏松杂志,2015,21(2):367-371.
[4] 赵光,沈霖,杨艳萍,等.青娥丸对绝经后骨质疏松症患者骨密度 、血清 M M P-2 水平及骨代谢指标的影响[J].中西医结合研究,2012,4(3):113-117.
[5] 梅艳洁,陈逸青,章秋.绝经后骨质疏松症与动脉钙化相关性的研究进展[J].安徽医药,2014,18(4):593-596.
[6] 丁颖,姜醒华.基质 Gla 蛋白与动脉钙化、骨质疏松关系的研究进展[J].实用临床医学,2010,11(7):129-132.
[7] 杨雅,赖晓阳,王平芳,等.基质GLA蛋白与绝经后骨质疏松症[J].中国骨质疏松杂志,2008,14(11):839-841.
[8] 钟文婷,姜醒华.MGP与绝经期妇女动脉硬化和骨质疏松的关系[J].中国循环杂志,2013,28:42.
[9] 翁泽斌,颜翠萍,张志杰,等.不同炮制品入药的青娥丸含药血清对人成骨细胞增殖、分化及矿化的影响[J].中国实验方剂学杂志,2015,21(6):165-168.
[10] 金树梅.加减青娥方对RAW264.7向破骨细胞分化的影响及机制探讨[C]∥世界中医药学会联合会内分泌专业委员会第一届国际中医内分泌学术会议,北京:2014:291-299.
[11] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松诊治指南(2011)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.
[12] 国家食品药品监督管理局.中药新药临床研究指导原则[M ].北京:中国医药科技出版社,2002:356-361.
[13] Xu XJ,Shen L,Yang YP,et al.Serum β-catenin levelsassociated with the ratio of RANKL/OPG in patientswith postmenopausal osteoporosis [J].Int J Endocrinol,2013,2013:534352.
[14] 刘政,吴倩,黄帅立.骨质疏松症的中医病因病机与治则研究[J].江苏中医药,2014,46(2):42-44.
[15] 王开.基质Gla蛋白(MGP)[J].国外医学泌尿系统分册,2005,25(3):413-415.
[16] Kinoshita H,Nakagawa K,Narusawa K,et al.A functional single nucleotide polymorphism in the vitamin-K-dependent gammaglutamyl carboxylase gene(Arg325gin)is associated with bone mineral density in elderly Japanese women[J].Bone,2007,10(2):451-456.
[17] Tuüón-Le Poultel D,Cannata-Andía JB,Román-García P,et al.Association of matrix Gla protein gene functional polymorphisms with loss of bone mineral density and progression of aortic calcification.[J].Osteoporos Int,2014,25(4):1237-1246.
[18] Price PA,Nguyen TM,Williamson MK.Biochemical characterization of the serum fotuin-mineral complex[J].Biol Chem,2003,278(24):22153-22160.
[19] 丁颖,姜醒华.基质 Gla 蛋白与动脉钙化、骨质疏松关系的研究进展[J].实用临床医学,2010,11(7):129-132.
[20] 牛煜.青娥丸治疗绝经后骨质疏松症疗效观察[J].深圳中西医结合杂志,2012,22(2):101-102.
[21] 孙冠芸,王星琴,薛冰洁,等.复方青娥丸不同萃取部位雌激素样作用研究 [J].重庆中草药研究,2011,64(2):37-40.
[22] 李璘,邱蓉丽,乐巍,等.补骨脂雌激素样作用实验研究[J].辽宁中医药大学学报,2012,14(4):57-58.
[23] 陈雪英,姜醒华,赖晓阳,等.雌二醇对去卵巢大鼠基质GLA蛋白表达的影响[J].中华妇产科杂志,2012,47(11):833-838.
[24] 颜翠萍,翁泽斌,吴育,等.青娥丸盐炙品与生品抗去卵巢诱导的骨质疏松效应的比较研究[J].南京中医药大学学报,2014,30(3):438-442.
[25] 徐晓娟,沈霖,杨艳萍,等.青娥丸对绝经后骨质疏松症患者骨密度和骨转换标志物的影响[J].中国中医骨伤科杂志,2013,21(6):9-10.
[26] 李萍,沈霖,杨艳萍.青娥丸治疗绝经后骨质疏松症(肾虚血瘀证)的临床研究[J].中西医结合研究,2014,6(6):281-285.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(81473492)
更新日期/Last Update: 2016-03-15